#oncology #NICE #AstraZeneca #dualimmunotherapy #advancedlivercancer #livercancer #Imfinzi #durvalumab #Imjudo #tremelimumab #Advancedhepatocellularcarcinoma #unresectablehepatocellularcarcinoma #HCC #NICEapproval #STRIDEregimen #primarylivercancer #BritishLiverTrust
zurl.co/M3ftp
zurl.co/M3ftp
NICE backs AstraZeneca’s dual immunotherapy for advanced liver cancer - PharmaTimes
Imfinzi and Imjudo combination recommended as first-line treatment
pharmatimes.com
September 9, 2025 at 8:18 AM